// App-Quantinova.ai

CT143 : Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers

Researchers

Presenter

  • Rajiv Shinde

Principal Investigators

  • Martin Little

  • Reece Caldwell

  • Roopa Kurup

  • Ruth Riisnaes

  • Mateus Crespo

  • Ruth Ruddle

  • Bora Gurel

  • Adam Stewart

  • Jenny King

  • Mona Parmar

  • Alison Turner

  • Florence Raynaud

  • Muneeb Mahmud

  • Christina Yap

  • Jonathan A. Pachter

  • Gordon B. Mills

  • Anna Minchom

  • Juanita Lopez

  • Susana N. Banerjee

  • Johann S. de Bono

  • Matthew Krebs

  • Udai Banerji

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Verastem Oncology, Needham, MA

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Colorectal Cancer

  • Gynaecological cancer

  • Lung Cancer

Biomarkers

  • Focal Adhesion Kinase

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • VS-6063

  • RO5126766

  • VS 6766

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Expansion Study

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03875820

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved